Recent aspects of riboflavin and UV‐a corneal crosslinking for keratoconus

Corneal crosslinking (CXL) has been proven to inhibit the progression of keratoconus and corneal ectatic disease. Over the last years, new treatment protocols have emerged, aiming to increase efficacy and safety of the procedure. Nowadays, a plethora of different modalities are available, such as ‘epi‐on’ and ‘epi‐off’ procedures, ‘accelerated’ CXL, ‘pulsed’ CXL, ‘customized’ CXL, etc. At the same time, riboflavin solutions have also evolved in order to provide improved outcomes. This talk will highlight the above mentioned innovations and evaluate their clinical relevance and importance, emphasizing on the ‘gold standard’ in CXL therapies, in an evidence‐based manner.